Bringing Patient Centricity to Life in Australian Healthcare

The current healthcare environment in Australia offers various opportunities for stakeholders, including patients, to engage with the health system and government in reform efforts. These opportunities arise from factors such as increased awareness of the importance of efficient approval processes for medicines and vaccines due to the COVID-19 pandemic, ongoing reviews of health technology assessment […]

Funding Innovative Medicines Whitepaper

Australia has a unique opportunity to reform the way it evaluates and funds medicines and vaccines, toensure that Australians are among the first in the world to access new technologies. This is a policyobjective of the Australian Government that is shared by the medicines industry. Reforms to Australia’sPharmaceutical Benefits Scheme (PBS) and National Immunisation Program […]

Strengthening Australia’s Approach to Horizon Scanning for New Therapies

Horizon scanning is a process or system which seeks to systematically identify and assess the potential impact of new and emerging health technologies on patients and other healthcare system stakeholders.  This facilitates proactive planning for the arrival of new health technologies. BMS convened the Shaping Healthcare Together Roundtable, under the Broadening the Evidence project, online […]

Submission to the PBAC on the Base Case Discount Rate

Discount rates reflect how society values future outcomes compared to present outcomes. When applied to medicines, inappropriately high discount rates disadvantage treatments which have longer term health benefits, such as preventative or curative treatments, disproportionately discriminating against patients who could benefit from treatments where the benefits are realised over a longer period of time. As […]

Broadening the Evidence Report

Australia’s national health technology assessment (HTA) processes include the assessment of all prescription medicines where a listing on the Pharmaceutical Benefits Schedule (PBS) is sought. Listing on the PBS ensures subsidised, affordable and equitable access to medicines for Australian patients. It is especially important for high cost new medicines that may deliver significant improvements in […]

Roundtable: Response and resilience of the Australian life sciences sector

As the world emerges from the pandemic, it is critical to reflect on what has been learned and how to make strategic and sustainable investments for the future. Australia must identify and prioritise local investments, co-designed with stakeholders, and collaborating with the global life sciences sector.  Effective investments have the potential to deliver benefits across […]